痛泻要方颗粒剂干预腹泻型肠易激综合征结肠黏膜VIP、SP表达的临床研究被引量：13

导出

摘要目的:观察痛泻要方颗粒剂治疗腹泻型肠易激综合征VIP、SP变化及其临床疗效,探讨痛泻要方的作用机理。方法:符合罗马Ⅲ诊断标准的100例D-IBS患者1∶1随机分为治疗组50例,对照组50例。治疗组予痛泻要方颗粒剂,每次1包,2次/d;对照组予得舒特50 mg,3次/d;疗程4 w。治疗前以及治疗4 w后进行临床信息采集包括腹痛评分、腹胀评分、大便性状及生存质量评分;采用免疫组化法检测治疗前、后结肠VIP、SP阳性细胞分布变化。结果:治疗组总有效率为88.0%,对照组总有效率为84.0%,两组总体疗效比较无统计学意义(P>0.05);治疗前,结肠黏膜VIP、SP阳性表达呈上升趋势,予痛泻要方治疗后,结肠黏膜VIP、SP阳性表达呈下降趋势,有统计学意义(P<0.05)。结论:痛泻要方可能通过抑制VIP、SP降低内脏高敏感性,有效缓解腹痛、腹胀,改变大便性状、减少排便次数,提高患者生存质量。

作者孔梅邢长永王莺

机构地区中山大学第五附属医院

出处《中药材》 CAS CSCD 北大核心 2010年第10期1668-1671,共4页 Journal of Chinese Medicinal Materials

关键词痛泻要方颗粒剂腹泻型肠易激综合征血管活性肠肽 P物质

分类号 R969.4 [医药卫生—药理学]

引文网络
相关文献

参考文献9

1Longstreth GF, Drossman DA. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs [ J ]. Clin Gastroenterol Hepatol, 2005,3 (4) :397-400.
2熊理守,陈旻湖,陈惠新,许岸高,王伟岸,胡品津.广东省社区人群肠易激综合征的流行病学研究[J].中华医学杂志,2004,84(4):278-281. 被引量：258
3Heading R, Bardhan K, Hollerbach S, et al. Systematic review: the safety and tolerability of pharmacological a- gents for treatment of irritable bowel syndrome-a European perspective [ J ]. Aliment Pharmacol Ther, 2006,24 ( 2 ) : 207 -236.
4胡品津.肠易激综合征诊治共识意见[J].中华消化杂志,2003,23(7):427-427. 被引量：157
5Drossman DA, Dumitrascu DL. Rome Ⅲ: New standard for functional gastrointestinal disorders [ J ]. Gastrointestin Liver Dis, 2006,15 ( 3 ) : 237-241.
6Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders [ M ]. Gastroenterology, 2006,130 (5) :1480-1491.
7Wu HG, Jiang B, Zhou EH, et al. Regulatory mechanism of electro acupuncture in irritable bowel syndrome: preventing MC activation and decreasing SP, VIP secretion[ J ]. Dig Dis Sci, 2008,55(6) :1644-1651.
8常晓兰,冯广友.肥大细胞与神经系统的相互作用[J].中国临床康复,2003,7(22):3110-3112. 被引量：16
9Frederickson RC, Burgis V, CE, et al. Dual actions of substance P on nociception: possible role of endogenous opioids[J]. Science, 1978,199(4335) : 1359-1362.

二级参考文献25

1屈纪富,程天民,郝利.参与皮肤伤口愈合的细胞及其作用的研究进展[J].中国组织工程研究与临床康复,2001,10(24):74-75. 被引量：56
2Dines KC, Powell HC. Mast cells interaction with the nervous system: relationship to mechanism of disease. J Neuropathol Exp Neurol 1997:56 ( 6 ): 627 - 40.
3Besedovsky K, Sorkin E. Network of immune-neuroendocrine interactions. Clin Exp Immunol 1977: 27(1): 1 -12.
4Goldschmidt RC, Hough LB, Glick SD, et al. Mast cells in rat thalamus: nuclear localization, sex difference and left-right asymmetry. Brain Res 1984; 323(2):209 - 17.
5Dimitriadou V, Buzzi MG, Moskowitz MA, et al. Trigeminal sensory fiber stimulation induces morphological changes.feflecting secretion in rat dura matter mast cells. Neuroscience 1991 : 44 ( 1 ) : 97 - 112.
6Theoharides TC. Mast cells: the immune gate to the brain. Life Sci 1990; 46:607 - 17.
7Campbell DJ, Kernan JA. Mast ceils in the central nervous system. Nature 1966;210(37): 756 -7.
8Dropp JJ. Mast cells in the human brain. Acta Anat (Basel) 1979; 105(4):505 - 13.
9Silverman AJ, Sutherland AK, Wilhelm M, et al. Mast ceils migrate from blood to brain. J Neurosci 2000; 20 ( 1 ) : 401 - 8.
10Artico M, Cavallotti C, Cavallotti D. Adrenergic nerve fibres and mast cells:correlation in rat thymus. Immunol Lett 2002:84 (1):69 -76.